{"id":45348,"date":"2022-06-22T13:01:43","date_gmt":"2022-06-22T11:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/trends-in-drug-benefit-design-report-released-by-pharmaceutical-strategies-group\/"},"modified":"2022-06-22T13:01:43","modified_gmt":"2022-06-22T11:01:43","slug":"trends-in-drug-benefit-design-report-released-by-pharmaceutical-strategies-group","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/trends-in-drug-benefit-design-report-released-by-pharmaceutical-strategies-group\/","title":{"rendered":"Trends in Drug Benefit Design Report Released by Pharmaceutical Strategies Group"},"content":{"rendered":"
\n

\nResults in PSG\u2019s latest benefit design research reveal an increased focus on member satisfaction<\/i>\n<\/p>\n

DALLAS–(BUSINESS WIRE)–New research on the latest trends in benefit design launches today. Pharmaceutical Strategies Group (PSG), an EPIC company, developed the Trends in Drug Benefit Design Report<\/i>\u2014sponsored by Rx Savings Solutions. The proprietary research uncovers salient insights into the perceptions and challenges around high deductible health plans (HDHPs), the role of member experience, formulary strategy, and how the Great Resignation and pandemic have shifted plan design priorities.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cPlan sponsors must constantly review trends and adjust plan design and programs to meet current needs and marketplace conditions,\u201d said Michael Lonergan, RPh, President of PSG. \u201cThis research puts a microscope on benefit design, offering insight into how to be proactive and innovative to create affordable and accessible pharmacy benefits.\u201d\n<\/p>\n

\nMember acceptance is a barrier to utilization management (UM) programs
\n
<\/b>A third of respondents cited reducing inappropriate utilization as their top goal outside of managing trend, but more than half (57%) of respondents consider lack of member acceptance a barrier to trend and UM programs.\n<\/p>\n

\nThe top challenge with formulary exclusions is member dissatisfaction
\n
<\/b>\u201cThe majority of respondents (69%) cite member dissatisfaction as their top challenge with formulary exclusions,\u201d said Morgan Lee, Senior Director of Research and Strategy at PSG. \u201cYet 81% of respondents use formulary exclusions.\u201d\n<\/p>\n

\nPlan design priorities shifting to accommodate current market dynamics: The Great Resignation, COVID-19
\n
<\/b>The report shows nearly half of respondents (41%) increased their focus on member experience since the start of the pandemic.\n<\/p>\n

\n\u201cPlan designs evolve, solutions come and go, and priorities shift. At the end of the day, consumers shoulder an increasingly unsustainable share of medical and pharmacy costs,\u201d said Michael Rea, PharmD, Founder and CEO of Rx Savings Solutions (RxSS). \u201cThe research conducted by PSG will help inform drug benefit design decisions that work toward an elusive but important goal, one that is underscored by the impact of COVID-19 and the Great Resignation.\u201d\n<\/p>\n

\nKey takeaways from the Trends in Drug Benefit Design Report<\/b> include:\n<\/p>\n